
The Salt Path Author Raynor Winn Breaks Silence On Controversy Surrounding Her Book
Over the weekend, The Observer published a report which cast doubt on the legitimacy of some of the claims outlined in Raynor Winn's 2018 book, which was marketed at the time as a memoir.
In Winn's writing, she speaks of how she and her husband Moth walked the 600-mile length of the South West Coast Path, in South West England, after being made homeless.
She also speaks of Moth's struggles with the neurodegenerative disease corticobasal degeneration (CBD), with which he was diagnosed shortly before the couple was made homeless.
However, The Observer's piece raised questions about a number of parts in the book, including exactly what led to the couple being made homeless, and specific parts of Moth's illness.
Posting on Instagram for the first time about the matter on Wednesday evening, Winn wrote: 'The last few days have been some of the hardest of my life. Heartbreaking accusations that Moth has made up his illness have been made leaving us devastated.
'To combat these vile and heinous accusations, with Moth's permission, and on the advice of his neurologist, I am releasing excerpts from three clinic letters, showing he is treated for CBD/S and has been for many years. This is deeply personal information that no one should ever be forced to share, but we feel we have no choice in the face of this unbelievably hurtful false narrative. The redacted sections are for the personal privacy of Moth and the doctors involved.'
Winn also released a longer statement on her website, which read: 'Over the past few days, I have had vitriol poured on me from all quarters, along with threats directed at me, my family, and our children. It has been incredibly hard to remain silent, something I've had to do while waiting to receive legal advice. That legal advice is ongoing, but I can now speak up.
'The Observer article [is] grotesquely unfair, highly misleading and seeks to systematically pick apart my life. But, as our walk along the Salt Path taught us, when life has ground you into the dirt, you need to stand up, turn your face to the wind, and continue, unafraid. So that is what I must do.'
She continued: ' The Salt Path is about what happened to Moth and me, after we lost our home and found ourselves homeless on the headlands of the south west. It's not about every event or moment in our lives, but rather about a capsule of time when our lives moved from a place of complete despair to a place of hope.
'The journey held within those pages is one of salt and weather, of pain and possibility. And I can't allow any more doubt to be cast on the validity of those memories, or the joy they have given so many.'
Winn added: 'It's important to say, the Observer were offered the opportunity, by my lawyers, to discuss in detail the allegations made against me to correct their inaccurate account and to be guided on the truth, on the basis that the discussion would not be made public.
'However, they chose not to take it, preferring to pursue their highly misleading narrative.'
She also responded directly to specific allegations outlined in The Observer's piece, most notably claims that Winn embezzled money earlier in her life before being made homeless.
'The dispute with Martin Hemmings, referred to in the Observer by his wife, is not the court case in The Salt Path. Nor did it result in us losing our home,' she wrote. 'Mr Hemmings is not Cooper [a character in The Salt Path ]. Mrs Hemmings is not in the book, nor is she a relative of someone who is.
'I worked for Martin Hemmings in the years before the economic crash of 2008. For me it was a pressured time. It was also a time when mistakes were being made in the business. Any mistakes I made during the years in that office, I deeply regret, and I am truly sorry.
'Mr Hemmings made an allegation against me to the police, accusing me of taking money from the company. I was questioned, I was not charged, nor did I face criminal sanctions. I reached a settlement with Martin Hemmings because I did not have the evidence required to support what happened.
'The terms of the settlement were willingly agreed by both parties; Mr Hemmings was as keen to reach a private resolution as I was. A part of that settlement was that I would pay money to Mr Hemmings on a 'non-admissions basis'. This is why we needed the money back from Cooper that we invested and I come on to that next.'
Read Raynor Winn's full statement on her official website here.
Since its release in 2018, The Salt Path has inspired two more books, with a fourth in the series reported to be in the pipeline.
Last year, it was also turned into a film, starring Gillian Anderson and The White Lotus star Jason Isaacs as its central couple.
A statement provided by Winn's legal team to The Observer said: 'The Salt Path lays bare the physical and spiritual journey Moth and I shared, an experience that transformed us completely and altered the course of our lives. This is the true story of our journey.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Alabama CBD Customers: SUNMED Stores Are Open and Thriving
Sunmed™ | Your CBD Store® welcomes Alabama CBD customers! BIRMINGHAM, Ala., Aug. 1, 2025 /PRNewswire/ -- Your Alabama Sunmed™ | Your CBD Store® locations are open for business and carrying a full inventory of compliant, clinically proven and high-quality premium hemp and CBD full and broad-spectrum products. In appreciation of its customers' continued support, participating SUNMED stores across Alabama are offering FREE Wellness Gummy ($60 value). Promo Code: VIPAL25* Sunmed always strives to offer consumers wellness and therapeutic products that meet the highest standards with respect to quality, consumer safety and satisfaction. Recently enacted regulatory changes in Alabama had little or no impact with respect to Sunmed's CBD and hemp products. Sunmed welcomes reasonable regulations that guarantee consumer's access to Sunmed's wide variety of wellness goods and provide Sunmed small business store owners with the opportunity to continue to serve the community. Across Alabama please visit any of Sunmed | Your CBD Store Locations – Sunmed CBD. Offer valid at participating stores while products last. Additional restrictions apply. Void where prohibited, this offer cannot be combined with other offers. Limit 1 per household. Contact Patrick ShatzerSunmed l Your CBD Storecustomersupport@ About Sunmed™ | Your CBD Store® Sunmed | Your CBD Store, an affiliate of Sunflora, Inc., is the largest hemp retailer in the United States and the exclusive home of award-winning, hemp-derived Sunmed products. With 260+ nationwide locations across 39 states, the brand offers a premium in-store customer experience with access to 150+ nonpharmaceutical wellness formulas, including clinically proven sleep gummies, pain relief topicals, USDA-organic oil tinctures, and CBD for pets. Through in-store education, community involvement, and groundbreaking clinical research, Sunmed strives to empower modern wellness and enhance people's lives with natural science-backed products. Learn more at View original content to download multimedia: SOURCE Sunmed Sign in to access your portfolio


Associated Press
6 days ago
- Associated Press
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ('Artelo' or the 'Company') (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that it has received written scientific advice from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on the nonclinical development and first-in-human (FIH) clinical study plans for ART12.11, a novel cocrystal of Cannabidiol (CBD) and Tetramethylpyrazine (TMP). The MHRA agreed that reliance on the substantial body of historic nonclinical and clinical evidence for CBD, alongside legacy data for TMP, provides a scientifically justified basis for a streamlined clinical trial application (CTA)-enabling nonclinical development plan of the cocrystal combination to support the proposed FIH study, with clear guidance for achieving the agreed-upon FIH study design for ART12.11. The agency also affirmed that the proposed first-in-human (FIH) study design—a single-dose, multi-formulation crossover study—was methodologically sound for characterizing ART12.11's pharmacokinetic profile. Importantly, the MHRA offered constructive and specific guidance for completing the data package supporting the agreed-upon Phase 1 trial. Additionally, the agency proposed that ART12.11 may be a candidate for the Innovative Licensing and Access Pathway (ILAP). ILAP offers a unique opportunity to accelerate the development and patient access of promising new therapies through early and sustained collaboration with the MHRA, National Health Service, and health technology assessment bodies. Given ART12.11's novel mechanism and potential to address unmet needs in anxiety and depression, Artelo believes the program aligns well with ILAP's criteria and will evaluate a formal application to enter the pathway in the coming months. 'It's gratifying to receive this positive feedback and actionable recommendations from the MHRA, which provides a clear path forward as we prepare to initiate clinical studies with ART12.11,' said Dr. Andrew Yates, Chief Scientific Officer at Artelo. 'The recommendation to explore ILAP reinforces the proposition of ART12.11 as a novel drug with the potential to transform the treatment landscape for anxiety and depression.' Multiple nonclinical studies with ART12.11 have shown its promising profile compared to an antidepressant or CBD alone. The Company recently announced positive preclinical results in a depression model comparing ART12.11 with sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), where Artelo's patented CBD:TMP cocrystal demonstrated efficacy on par with sertraline and showed superior cognitive restoration compared to the leading SSRI. Additionally, in a rodent model of stress-induced anxiety and depression, where ART12.11 was compared to CBD dosed at 300% the amount of CBD contained in the oral tablet of ART12.11, the CBD:TMP cocrystal demonstrated efficacy where CBD alone did not. 'The clear regulatory assurance from the regulatory authority in the UK is expected to reduce expenses for our ART12.11 program,' added Gregory Gorgas, President & CEO at Artelo. 'We are especially pleased with the potential for an accelerated development strategy which could greatly accelerate our progress with ART12.11 and could provide for a longer period of market exclusivity as our patents are valid in 20 countries through the end of 2038. Over the next few months we look forward to finalizing our preparations to enter the clinic with ART12.11 early next year.' About ART12.11 ART12.11 is Artelo's wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Greatly enhanced pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile in a solid dosage form may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The U.S. issued composition of matter patent for ART12.11 is enforceable until December 10, 2038, and has now been granted or validated in 19 additional countries. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and Twitter: @ArteloBio. Forward Looking Statements Investor Relations Contact: Crescendo Communications, LLC Tel: 212-671-1020 Email: [email protected]

Epoch Times
30-07-2025
- Epoch Times
Study Finds Elevated Liver Enzymes in Healthy Adults Using Cannabidiol
Healthy adults who took doses representative of consumer use of cannabidiol (CBD) daily for four weeks showed significant increases in liver enzymes—though no actual liver damage—in the first controlled trial to examine the cannabis compound's effects on liver function, researchers reported in JAMA Internal Medicine. CBD is a common chemical compound found in the cannabis plant, specifically in both hemp and marijuana. Unlike tetrahydrocannabinol (THC), another common cannabinoid, CBD does not produce a psychoactive effect, also called the 'high.'